$14.9M capital deployed

28% primary ownership

Sep '11 initial capital deployed

return to top

Why Putney?

Headquartered in Portland, ME, Putney is a rapidly growing pet pharmaceutical company focused on developing high-quality, generic prescription medicines for pets.

Putney’s mission is to provide veterinary practices with FDA approved veterinary generic medicines that meet pet medical needs and offer cost-effective alternatives for pet owners.

According to IMS Health, 86% of all human prescriptions in the U.S. are filled with a generic, yet very few generics exist for drugs prescribed for pets. Analysis of the FDA Center for Veterinary Medicine’s approvals reveals that 91% of FDA-approved drugs for pets have no generic equivalent. The overall size of the pet pharmaceutical market is significant. Data presented at the FTC Pet Medication Workshop in October 2012 showed that Americans spend $7 billion annually on pet medicines. According to Vetnosis, this sector is projected to grow at a compound annual rate of 5% per year between 2011 and 2016.

In January 2015, Putney received its fifth FDA approval in five months, for its Enrofloxacin Antibacterial Injectable Solution. Putney has received eight approvals for generic drugs for pets out of the 17 in total granted by FDA’s Center for Veterinary Medicine from 2012 to January 2015. During the fourth quarter of 2014, Putney launched Carprofen Chewable Tablets, the first generic that is equivalent in dosage form to Zoetis’ popular Rimadyl® Chewable Tablets, which has estimated sales of $70 million. To date, Putney has commercialized nine FDA-approved veterinary generic drugs from its pipeline, and is the only company with FDA approvals for generics of all dosage forms used for companion animals of both enrofloxacin and carprofen.